Eli Lilly and Company (NYSE:LLY) – Research analysts at SunTrust Banks lowered their FY2022 earnings per share estimates for shares of Eli Lilly and in a research note issued to investors on Tuesday, May 15th. SunTrust Banks analyst J. Boris now anticipates that the company will earn $7.77 per share for the year, down from their previous estimate of $7.78.
LLY has been the topic of a number of other reports. Jefferies Group set a $90.00 price target on shares of Eli Lilly and and gave the stock a “buy” rating in a report on Friday, April 13th. Credit Suisse Group set a $80.00 price objective on shares of Eli Lilly and and gave the company a “hold” rating in a report on Sunday, April 22nd. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Monday, March 26th. JPMorgan Chase set a $105.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a report on Monday, February 26th. Finally, Bank of America decreased their price objective on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and an average target price of $93.21.
Shares of Eli Lilly and opened at $82.07 on Friday, according to MarketBeat.com. Eli Lilly and has a 1 year low of $73.69 and a 1 year high of $89.09. The firm has a market cap of $88.12 billion, a P/E ratio of 19.18, a PEG ratio of 1.40 and a beta of 0.26. The company has a current ratio of 1.41, a quick ratio of 1.01 and a debt-to-equity ratio of 0.64.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.13 by $0.21. Eli Lilly and had a net margin of 4.82% and a return on equity of 35.37%. The firm had revenue of $5.70 billion for the quarter, compared to the consensus estimate of $5.51 billion. During the same period in the prior year, the firm posted $0.98 earnings per share. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date is Wednesday, May 16th. Eli Lilly and’s dividend payout ratio (DPR) is 52.57%.
In other news, insider Donald A. Zakrowski sold 876 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $77.55, for a total value of $67,933.80. Following the completion of the sale, the insider now directly owns 4,130 shares in the company, valued at $320,281.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 140,000 shares of the stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $81.97, for a total transaction of $11,475,800.00. Following the completion of the sale, the insider now owns 122,755,804 shares of the company’s stock, valued at $10,062,293,253.88. The disclosure for this sale can be found here. Insiders sold 361,472 shares of company stock valued at $29,328,215 over the last quarter. Company insiders own 0.11% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of LLY. Franklin Resources Inc. raised its position in shares of Eli Lilly and by 14.1% in the first quarter. Franklin Resources Inc. now owns 32,541,775 shares of the company’s stock valued at $2,517,762,000 after buying an additional 4,022,251 shares during the last quarter. Schroder Investment Management Group increased its position in Eli Lilly and by 103.8% during the first quarter. Schroder Investment Management Group now owns 4,689,223 shares of the company’s stock worth $362,806,000 after purchasing an additional 2,388,548 shares during the last quarter. Investec Asset Management LTD acquired a new stake in Eli Lilly and during the fourth quarter worth about $163,570,000. BlackRock Inc. increased its position in Eli Lilly and by 3.0% during the first quarter. BlackRock Inc. now owns 65,780,446 shares of the company’s stock worth $5,089,436,000 after purchasing an additional 1,926,334 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its position in Eli Lilly and by 110.9% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,832,626 shares of the company’s stock worth $154,783,000 after purchasing an additional 963,776 shares during the last quarter. Institutional investors and hedge funds own 78.32% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.